Sarah Kane
Associate Director, HEOR
专长:
Sarah has 10+ years of professional experience across biotechnology and HEOR sectors. Within the Value & Evidence team at EVERSANA, Sarah supports numerous aspects of HEOR, including economic modelling, systematic literature reviews, meta-analyses and value communications.
Sarah joined EVERSANA after 4+ years in the biotechnology sector where she was involved in a wide range of projects including development of a commercial canine probiotic, microbial food sampling, and pharmaceutical product development. She holds a Ph.D. in Molecular Microbiology from the University of Alberta and a B.Sc. in Biomedical Science from the University of Waterloo.
Since joining EVERSANA, Sarah has been involved in a variety of projects including cost calculator/model development (Excel BIM/CUA and BaseCase), literature reviews (structured and systematic), meta-analyses, development of various value communication tools and preparation of interactive slide decks, sales force tools, manuscripts, and abstracts.
Sarah has experience across a variety of therapeutic areas spanning cardiovascular disease, neurovascular disease, ophthalmology, oncology and hematology.
Articles by Sarah Kane
Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Since the FDA’s approval of palbociclib plus letrozole in 2015, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), have become the standard of care for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced/metastatic breast cancer (HR+/HER2- LABC/mBC) in the first-line (1L) treatment setting. However, there is no clear standard […]
Real-World Insights: Effectiveness and Safety of Crizotinib in ROS1-Rearranged NSCLC
Lung cancer is one of the most incident malignancies and the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and, with the emergence of genomic techniques, tumor genotyping has led to the identification of actionable driver alterations in NSCLC. The ROS1 gene encodes a tyrosine […]